Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and
efficacy of tulisokibart in participants with moderate to severe hidradenitis
suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior
to placebo wi...
Age: 18 - 75 years
Gender: All
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of
remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate
to severe hidradenitis suppurativa (HS).
Age: 18 - 100 years
Gender: All
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Age: 18 - 100 years
Gender: All
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease
which includes the forming of lumps, abscesses and scars in areas of the skin such as
under the breasts, under armpits, inner thighs, groin and buttocks. This study will
compare lu...
Age: 16 years - 66+
Gender: All